Chief Executive Officer
Trond Williksen is highly experienced in the international aquaculture and seafood industries, having held senior executive positions in the sector for over 20 years. Most recently he was CEO of SalMar ASA, the Norwegian fish farm company and one of the world’s largest producers of farmed salmon. Prior to this, he was CEO of AKVA group ASA, the leading global aquaculture technology and service provider for six years. He previously held a number of senior roles in Aker ASA’s Seafoods, Ocean Harvest and BioMarine divisions.
Trond has also held a number of advisory and non-executive director roles in the industry including as Chairman of the Board of The Research Council of Norway, Oceans Portfolio; Chairman of Mørenot Group, which provides solutions to fishery and aquaculture customers; Chairman of the Board of Calanus AS, a biomarine company; and Board Member of SinkabergHansen AS, a Norwegian integrated aquaculture company.
Chief Financial Officer
Septima joined Benchmark from Dechra Pharmaceuticals PLC, the international provider of specialist veterinary pharmaceuticals and products, where she spent four years. Having joined as Group Financial Controller she was Acting CFO between 2016 and 2017. She was most recently Corporate Development Director overseeing all aspects of acquisition activities, strategic projects, business development and investment initiatives playing a significant role in supporting Dechra during a period of high growth.
Peter has a strong track record in growing successful international pharmaceutical and healthcare businesses. He is most renowned for his achievements as CEO of Clinigen Group plc, the FTSE AIM global pharmaceutical and services company, which he founded in 2010 and grew into close to a £1bn market cap company having acquired several businesses and expanded its international footprint.
Peter also serves as Chairman of Ergomed plc, the AIM-listed provider of clinical research, drug development and safety services internationally. He is also an Entrepreneur in Residence at Oxford Science Innovations.
Prior to Clinigen, he held a number of senior roles in the pharmaceutical and healthcare sectors including Chief Executive Officer of Penn Pharmaceutical Services. He co-created Unilabs Clinical Trials International in 1997, which was successfully sold to Icon plc in 2000.
Chief Scientific Officer
Alex has a strong track record in the animal health sector with more than 18 years’ experience in global public companies as well as start-ups. He most recently was the Director of Global R&D, AgriBusiness at Thermo Fisher Scientific, the American multinational biotechnology product development company, listed on the NYSE. In this role he drove the agribusiness innovation and growth strategy, and was focussed on the execution of the agribusiness product commercialisation pipeline across a range of R&D and manufacturing sites globally.
Prior to this, Alex led R&D divisions at biotechnology firms including Prionics AG and Cytos Proteome Therapeutics.
Alex holds a PhD in Pharmacology from the University of Zurich and an MSc from the Swiss Federal Institute of Technology.
Susan has over 20 years’ experience working in a variety of commercial, business development, manufacturing and operational roles including investing in growing technology businesses, acquisitions and the exploitation of new technologies. She co-founded Touchstone Innovations plc (acquired by IP Group plc), one of the world’s leading technology venture investment businesses, and served as its CEO from 2002 to 2013.
She was the former chair of Mercia Technologies PLC, a regional technology and biotech investor and holds an MA in Chemistry from Exeter College, Oxford.
Susan brings to Benchmark plc a wealth of experience having served on a variety of company boards. Her current roles include: Senior Independent Director and Remuneration Chair of Horizon Discovery Group plc; Non-Executive Director of QinetiQ Group plc and Chair of Schroder UK Public Private Trust plc (SUPP).
Kevin is a qualified Chartered Accountant with over 30 years’ of financial experience in international business and the biosciences industry, including with FTSE 100 companies.
Kevin has, for the past 11 years, been Chief Financial Officer at Berendsen plc, the leading FTSE 250 European textile service business. Previously, Kevin held senior finance positions within biosciences group Amersham plc and before that was a partner with PricewaterhouseCoopers (Prague). Kevin holds a BA in French from University College, Durham.
Other roles: Chief Financial Officer of Berendsen plc.
Hugo has over 35 years of experience in the animal health and pharmaceuticals industry, firstly with GlaxoSmithKline, and more recently with Merck during a period of major growth in the organisation.
Hugo held the post of Chief Commercial Officer Animal Health at Merck, having responsibility for Merck’s commercial operations worldwide. Since stepping down from that role in 2012, Hugo has acted as an independent senior advisor with several multinational companies, private equity groups and consulting firms primarily in the animal health sector. Hugo brings a wealth of international experience to the board of Benchmark, alongside his expertise in aggressively growing businesses and in the commercialisation of medicines and animal health products.
Yngve has more than 20 years experience in the aquaculture sector as a senior executive, adviser and investor. Yngve was chief executive of leading Norwegian salmon producer Salmar, and of international white fish supplier Aker Seafood during periods of successful growth.
He is now chairman of Chilean salmon producer Nova Austral, and sits on the board of Mediterranean fish producer Andromeda. Yngve also acts as strategic adviser to investors in the aquaculture sector. Yngve has a very strong track record in Benchmark’s focus area of aquaculture, both in the Norwegian and international markets.
Kristian has more than 13 years experience as an investment professional with a particular focus on the aquaculture, pharmaceuticals, energy and renewables sectors. Kristian is currently an Investment Professional and Co-Head of Ferd Capital, a division of Ferd AS, a Norwegian investment company holding 26% of the Company’s issued share capital. Prior to that, he was a Partner at Herkules Capital, a leading private equity firm in Norway. Before this, he was a research analyst at First Securities, an investment banking firm. Kristian has held various board positions and is currently a Board Director of a number of companies including Fjord Line AS, a Scandinavian cruise and ferry operator.
Company Secretary & Group Legal Counsel
Jennifer is a French qualified Solicitor with over 10 years’ experience. Jennifer previously worked in French law firm SCP de Poulpiquet & Co and more recently as an in-house legal counsel for KellyDeli, a European sushi retail company where she gained experience in the salmon industry, focusing on commercial agreements, corporate and competition law.
Since joining Benchmark, Jennifer has been advising and supporting Group companies to execute their strategies. Jennifer holds a MA in Law from the university of Nice and “Diplome de Notaire”.
Head of Advanced Nutrition
Athene joined Benchmark in 2014 as Group Legal Counsel, having spent 10 years working as a qualified solicitor with Slaughter and May and Travers Smith in London, with brief stints in Hong Kong and Tokyo. Between 2014 to 2019, Athene built the Group’s Legal and IP function; was involved with acquisitions, corporate finance and integration projects; oversaw the IT team; and sat on the PLC Board as Company Secretary, Operations Board and divisional Boards.
In July 2019, Athene was appointed Managing Director of the Group’s Advanced Nutrition division, INVE Aquaculture. She is also a member of the Group’s Sustainability Committee. Athene holds an MA in Jurisprudence from St John’s College, Oxford.
Head of Animal Health
John is Technical Director of Fish Vet Group (FVG) & Benchmark Vaccines Limited (BVL). John has a degree in Agricultural and Environmental Science (honours in Crop Protection) from Newcastle University and an MBA from Open University with Business Finance and Acquisition Strategy from Harvard University.
He has 20 years experience in the animal health industry working in R&D, sales and marketing, business development, business unit leadership and leads the Group’s R&D teams working on the development, sales and marketing of new animal health vaccines, medicines and biocides. John joined FVG from Novartis Animal Health in 2011 where he was their Head of European Business unit Aquaculture and Head of Global Technical Services – Aquaculture, spending the past 12 years growing the Novartis Aquaculture business and taking to market many new vaccines and pharmaceutical products.
Head of Genetics
Jan-Emil joined SalmoBreed as Chairman of the Board in 2011 and managing director in 2013. Prior to this he has been working 10 years with Norwegian branded food company Rieber (Toro) and 15 years in the family company Fossen AS (today Lerøy Fossen AS).
Fossen was one of the pioneers in Norwegian fish farming with special focus on trout and value added products. During his time with SalmoBreed Jan-Emil has prepared the company for an ownership change and now looks forward to a new era for the company together with Benchmark and Stofnfiskur colleagues. Jan-Emil holds a MSc in Business Administrations and Economics as well as University courses in Aquaculture. He lives in Bergen with his wife and 3 children. He enjoys skiing in the winter and water sports and boatlife in the summer.
Head of Knowledge Services
James is Managing Director of 5M Publishing. James has an MBA and an MA in history (Magdalene College, Cambridge).
James has over twenty years’ experience in professional and education publishing first with Longman from 1987 to 1993 as an editor and publisher and then at Pearson Group PLC from 1993 to 2003 working in publishing and business development roles until he became Managing Director at FT Information Europe.
Prior to joining Benchmark in 2012 James was Managing Director at KBC, an international education provider.
Head of People
Anna has extensive experience in administration and HR having previously worked for the University of Oxford where she managed an ESRC Research Programme and the BBC where she focussed on training and development of Senior Executives.
Anna is responsible for employee development, relations, HR policies and payroll and works with the Executive team and group company boards to deliver the group people strategy. Anna is a graduate of Wye College (London University) with a degree in Animal Science and has a Diploma in Environmental Conservation from the University of Oxford.
Director of Investor Relations and Corporate Development
Ivonne joined Benchmark in 2017 after 20 years as Corporate Finance adviser at Cenkos Securities and Merrill Lynch. Throughout her career Ivonne has advised UK and international companies on a broad range of corporate finance transactions including IPO’s, fundraisings and M&A as well as on investor communications, corporate governance and regulatory matters. Ivonne holds a BSc in Engineering and an MBA from the Wharton School of Business.
Group Marketing Director
Doerte gained over 20 years professional experience in leadership functions related to innovation management, product management, new business development and marketing & sales. She built her professional profile by having worked at leading multinational B2C and B2B players related to the LifeScience and Packaging industry; such as Mars, Boehringer, DSM and Amcor.
She holds a PhD in Chemistry from the Technical University Clausthal (Germany), an executive MBA from Henley Management College (UK) and a Diploma in Business Psychology from Heriot Watt University (UK).
Rachel joined Benchmark in 2011 and is currently Benchmark’s Communications Manager. She was appointed Employee Representative in March 2020 to strengthen the employee voice in the board room in line with the new Corporate Governance guidelines.